Objectives: To evaluate whether patients with Cushing's syndrome (CS) had i) changes in coagulative and fibrinolytic parameters associated with CS activity and ii) higher prevalence of venous thromboembolic events (VTE). Design: Prospective study conducted on patients with CS evaluated at diagnosis and 12 months after surgery. Patients and methods: Forty patients with active CS (36 with Cushing's disease (CD) and 4 with an adrenal adenoma) were evaluated. Forty normal subjects and 70 patients with non-ACTH-secreting pituitary adenomas served as controls. All patients and controls underwent an assessment of coagulation and fibrinolysis indexes before and after surgery. Results: CS patients at baseline had a hypercoagulative phenotype when compared with normal subjects (activated partial thromboplastin time (aPTT), fibrinogen, D-Dimer, von Willebrand factor (VWF), plasminogen activator inhibitor 1 (PAI-1 or SERPINE1), antithrombin III (ATIII or SERPINC1), P!0.0001, a 2 antiplasmin, PZ0.0004, thrombin-antithrombin complex (TAT), PZ0.01, factor IX (F9), PZ0.03). Patients with still active disease after surgery had higher coagulative parameters than those in remission (VWF (P!0.0001), PAI-1 (PZ0.004), TAT (PZ0.0001), ATIII (PZ0.0002) and a 2 antiplasmin (or SERPINF2; PZ0.006)), whereas aPTT levels (PZ0.007) were significantly reduced. VTE occurred in three patients with CD (7.5%): one had a pulmonary embolism and two patients had a deep venous thrombosis; no patients submitted to transsphenoidal surgery for non-Cushing's pituitary adenoma had VTE (PZ0.04). Conclusions: Patients with CS have a procoagulative phenotype due to cortisol-associated changes in haemostatic and fibrinolytic markers, leading to increased incidence of VTE. Thromboprophylaxis seems to be appropriated in patients with active disease, particularly in the postoperative period.
Introduction
Endogenous Cushing's syndrome (CS) is a clinical state sustained by prolonged, inappropriate exposure to excessive endogenous secretion of cortisol. This condition may result from excessive ACTH production from the pituitary gland, ectopic ACTH secretion or excessive autonomous secretion of cortisol from a hyperfunctioning adrenocortical tumour. CS is associated with central obesity, hypertension, diabetes or insulin resistance, conditions that lead to an increased cardiovascular and thromboembolic risk (1) (2) (3) (4) . Moreover, it has been demonstrated that CS is associated with a hypercoagulable state and increased incidence of venous thromboembolic events (VTE) (5) (6) (7) (8) (9) . Some studies showed a shortening of the activated partial thromboplastin time (aPTT) (10) (11) (12) and elevated levels of factor VIII (F8), factor IX (F9) and von Willebrand factor (VWF) in CS with a consequent increased prevalence of cardiovascular disease such as ischaemic disease, cerebrovascular disease, vascular peripheral and lung disorders (10) (11) (12) (13) (14) (15) (16) (17) (18) . Patients with CS also showed an impairment of the fibrinolytic system due to an excess of the fast-activating plasminogen activator inhibitor 1 (PAI-1 or SERPINE1) (19) . A recent retrospective observational study showed that prophylactic anticoagulant therapy may reduce the incidence of VTE in a large cohort of patients with hypercortisolism (9) . These data support the evidence of a severe prothrombotic state in CS and mark the importance of a correct assessment of thromboembolic risk in these patients to prevent VTE.
The aims of this prospective study were to evaluate whether patients with CS had i) changes in coagulative and fibrinolytic parameters associated with CS activity and ii) higher prevalence of VTE.
Patients and methods

Study population
Forty patients (32 women, 8 men, 20-65 years) with untreated CS were enrolled in the study after their informed consent had been obtained. Thirty-six patients were affected by Cushing's disease (CD) caused by a corticotroph pituitary adenoma (32 micro-and 4 macroadenoma), and four had an adrenal adenoma (AA). Diagnosis of CD was mainly based on i) clinical features of hypercortisolism; ii) absence of a circadian rhythm of serum cortisol in terms of an elevated midnight sleeping cortisol level; iii) elevated 24-h urinary free cortisol (UFC) level (at least 1.5-2 times the upper limit of normal range) with inappropriately high morning plasma ACTH concentrations (O20 pg/ml); iv) failure of serum cortisol suppression (!18 ng/ml) after low-dose dexamethasone suppression test (LDDST) but O50% decrease after high-dose oral dexamethasone suppression test overnight (HDDST); v) magnetic resonance imaging (MRI) confirmation of a pituitary micro-or macroadenoma and vi) inferior petrosal sinus gradient O3 after CRH stimulation when appropriate. Diagnosis of ACTH-independent CS was based on points i) and ii) associated with elevated UFC levels and suppressed morning plasma ACTH concentrations (!10 pg/ml) and the evidence of an adrenal lesion by computed tomography (CT) scan (20, 21) .
Hypertension was present in 24 of 40 (60%) patients and was treated by a different combination of antihypertensive drugs, whereas diabetes mellitus was present in 10 (25%) patients under dietary and medical therapies. At the time of haemostatic and fibrinolytic marker evaluations, no patient was taking drugs to affect coagulation tests or assumed oestrogen therapy, which could affect cortisol concentrations. All CS patients submitted to adrenal and pituitary surgery started replacement therapy with cortone acetate at a total dose of 25-37.5 mg daily in two administrations, immediately after the operation. Subsequently, when adrenal function was recovered, the replacement therapy was tapered and then interrupted. Among patients with AA, all recovered a normal adrenal function between 3 and 6 months after surgery. Among 13 patients with persistent CD, 11 stopped cortone acetate few weeks after surgery, while 2 patients interrupted glucocorticoid replacement therapy between 4 and 5 months after surgery. Among 27 patients with remission of disease, 20 did not receive any glucocorticoid replacement therapy, while 7 patients received 25-37.5 mg of cortone acetate daily in two administrations. At 12 months, all patients with glucocorticoid replacement therapy showed normal serum cortisol and plasma ACTH values after 2-3 h from the administration of cortone acetate. In these patients, serum electrolytes and blood pressure were normal. No patients with CS had a positive family history of clotting disorders or VTE.
Forty normal subjects (29 women and 11 men, 24-65 years) included in the study at a 1:1 ratio and matched for sex and age served as controls for comparing coagulation indexes (coagulation controls). In the period 2005-2008, 55 patients (22 women and 33 men, 28-68 years) with non-functioning pituitary macroadenoma and 15 patients (9 women and 6 men, 24-62 years) with GH-secreting micro-and macroadenoma were submitted to pituitary adenomectomy. There was statistically significant difference in body mass index (BMI) between untreated CD versus coagulation control (PZ0.0013) and VTE control (P!0.0001). Among the 55 patients with non-functioning pituitary macroadenoma submitted to pituitary adenomectomy, 2 patients (3.6%) had complete hypopituitarism, 19 (34.5%) had partial hypopituitarism, 7 (12.7%) had isolated GH deficiency (GHD) and 2 (3.6%) presented isolated hypogonadism secondary to hyperprolactinaemia due to pituitary stalk compression. In all patients, pituitary dysfunction was corrected with appropriate replacement therapy with the exception of GH that was not administered to the GHD patients until the disappearance or the stability of the pituitary lesion was proven by MRI. Among the 15 patients with acromegaly, 9 patients were well controlled by somatostatin analogues therapy, while 6 patients had insulin-like growth factor 1 values above the normal range, despite somatostatin therapy. This control group was used for comparing the effects of surgery on VTE (VTE controls). No control subject or non-CS patient submitted to surgery had a predisposing condition and familiarity for VTE. The main clinical features of patients and controls at the study entry are shown in Table 1 .
Study design
This is a prospective study conducted at the Department of Endocrinology, University of Pisa, from January 2005 to January 2008. The study was approved by the Ethical Board of the Department of Endocrinology. At baseline, the study protocol included an accurate clinical history and a physical examination with the evaluation of BMI, systolic and diastolic blood pressure and heart rate. The hormonal evaluation included a blood sample for measuring serum cortisol obtained at 0800, 1600 and 2400 h, for plasma ACTH at 0800 h and for UFC, for which the mean of two urinary collections was considered. CRH test was performed after the i.v. administration of 100 mg ovine CRH Dexamethasone at a dose of 0.5 mg for the LDDST was administered orally strictly every 6 h for 48 h, and at a dose of 8 mg for the HDDST administered at 2400 h. Blood samples were collected for serum cortisol measurement at 0800 after 48 h following the first dose of dexamethasone for LDDST and at 0800 the next morning following a high dose of dexamethasone. MRI confirmation of a pituitary micro-and macroadenoma or an inferior petrosal sinus sample (IPSS) was performed when required. Patients with CD underwent transsphenoidal surgery, while those with AA were treated by laparoscopic adrenalectomy. A confirmed diagnosis of CD or AA was made on the basis of demonstration of pituitary corticotroph adenoma or AA at pathological examination. The decision to treat CD and AA with surgery was taken independently from the coagulation conditions. Patients were strictly monitored for 15 days after surgery; subsequent evaluations were made 1, 3, 6 and 12 months after surgery, including serum cortisol at 0800 h, plasma ACTH at 0800 h and UFC measurements. Coagulation and fibrinolysis indexes were evaluated at enrolment in the study and after 12 months after the definition of persistence/recurrence or remission of hypercortisolism.
Diagnosis of remission was based on i) regression or disappearance of clinical features of hypercortisolism; ii) restored circadian rhythm of serum cortisol; iii) normal UFC levels; iv) normal cortisol suppression after low-dose dexamethasone test; v) normal plasma ACTH concentrations (O15 pg/ml) for AA and vi) the absence of pituitary or adrenal lesion by MRI or CT scan (20, 21) .
Although CS is believed to be associated with an increased occurrence of VTE, no prospective study showing the efficacy of anticoagulant therapy have been reported so far; therefore, prophylaxis is not performed routinely in our Department. IPSS was performed in 19 patients with ACTH-secreting pituitary microadenoma. All patients, after IPSS, underwent antithrombotic prophylaxis with subcutaneous nadroparin calcium, a low molecular-weight heparin, at doses of 5700-7600 IU for 2 weeks.
All patients with CS and those with non-functioning pituitary adenoma and acromegaly were submitted to an accurate clinical history and a physical examination. The diagnosis of deep vein thrombosis (DVT) was performed by an ultrasound compression technique and confirmed by phlebography. The diagnosis of pulmonary embolism was performed by perfusion pulmonary scan.
Hormone assays
Serum cortisol (Immunotech, Marseille, France), plasma ACTH (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA) and UFC (DSL-2100 active, cortisol RIA, Webster, TX, USA) were assayed by commercial kits. Normal values used in our laboratory were as follows: early morning cortisol, 85-260 ng/ml; ACTH, 9-52 pg/ml and UFC, 36-120 mg/24 h.
Coagulation and fibrinolysis evaluation
All patients and coagulation controls underwent an assessment of coagulative and fibrinolytic markers before (time 0) and after surgery (time 12 months). The AB0 blood group was evaluated in patients and controls. All coagulation and fibrinolysis indexes were 
Results
Coagulation and fibrinolysis indexes at baseline
Patients with untreated CS had procoagulative phenotype owing to higher values of fibrinogen, D-Dimer, PAI-1, ATIII (P!0.0001), VWF (blood group 0, PZ0.007; blood group non-0, P!0.0001), a 2 antiplasmin (PZ0.0004), TAT (PZ0.01), F9 (PZ0.03), and a reduction of aPTT levels (P!0.0001) than controls ( Table 2) . No correlations at baseline were found among coagulation, fibrinolysis indexes and serum cortisol or UFC. We did not find any association between BMI and haemostatic variables (data not shown). Twenty-seven out of forty patients (67.5%) had remission of disease: all patients with adrenal disease and 23 of those with pituitary disease. The remaining 13 patients had persistent hypercortisolism. Patients with still active disease after surgery had higher coagulative parameters than those with cured disease (VWF (all, P!0.0001; blood group 0, PZ0.007; blood group non-0, PZ0.003), PAI-1 (PZ0.004), TAT (PZ0.0001), ATIII (PZ0.0002) and a 2 antiplasmin (PZ0.006)), whereas aPTT levels (PZ0.007) were significantly reduced (Table 3 and Fig. 1 ).
Changes in coagulation indexes in each patient before and after surgery are shown in Table 4 . The number of patients with VWF (all, PZ0.0003, blood group non-0, PZ0.004) and ATIII (PZ0.001) above normal ranges was higher in the untreated group than in patients with remission of disease after surgery ( Fig. 1 and Table 4 ).
Incidence of VTE in the study groups VTE occurred in three patients with CD (7.5%), whereas no thromboembolic events occurred in patients with remission of the disease (PZ0.02): one had a pulmonary embolism (2 days after transsphenoidal surgery), whereas 2 patients had deep vein thrombosis (one before surgery and one 2 months after surgery, while hypercortisolism was persistent). The two patients with DVT and the patient with pulmonary embolism (PE) had clearly abnormal coagulation parameters (Table 5) . On the contrary, 55 patients with nonfunctioning pituitary macroadenoma and 15 patients with acromegaly due to GH-secreting pituitary microor macroadenoma did not have thromboembolic events neither before nor after surgery (PZ0.04).
Discussion
The presence of procoagulative phenotype, which may be responsible for the increased risk of VTE, has already been described in patients with CS (22) . However, a recent systematic review focussed attention on the absence of a high-quality study (23) . The causes were several i) absence of prospective studies due to the rarity of the disease; ii) limited number of the coagulation test performed; iii) negligence in defining patients and control groups; iv) unclear timing of coagulation tests; v) inadequacy of follow-up period and vi) poor attention focussing on the occurrence of VTE.
The current data provide the largest perspective study conducted in patients with CS before and after surgery and in normal subjects. These data suggest that patients with CS showed increased levels of fibrinogen, D-Dimer, VWF, PAI-1, ATIII (P!0.0001), a 2 antiplasmin (PZ0.0004), TAT (PZ0.01) and F9 (PZ0.03) and reduced levels of aPTT (P!0.0001) compared with Table 3 Comparison of coagulation and fibrinolysis indexes in patients with Cushing's syndrome before and after surgical therapy.
Untreated
(nZ27) controls. In addition, concentrations of VWF (P!0.0001), TAT (PZ0.0001), ATIII (PZ0.0002), PAI-1 (PZ0.004), a 2 antiplasmin (PZ0.006) and aPTT (PZ0.007) tend to normalise after successful surgery. On the contrary, patients with persistent hypercortisolism after surgery did not have changes in mean values of coagulation parameters (Tables 3 and 4) . Despite the clinical data available, the pathogenesis of prothrombotic tendency is not yet clear. The most likely pathogenetic mechanism is represented by a cortisol-induced up-regulation of mRNA transcription of coagulation parameters and secondarily by the increased activity of fibrinolysis indexes (24, 25) . VWF plays a major role in primary haemostasis by promoting blood platelet adhesion to the subendothelium of the vessel wall. Corticosteroids are known to increase plasma VWF concentrations by acting on the rate of synthesis by the endothelial cells of the vessel wall (26) (27) (28) . In patients with CS, the increased plasma VWF levels are usually accompanied by an increase of TAT, as demonstrated in this study, which is an index of thrombin activity. PAI-1 is the main inhibitor of the fibrinolytic system; however, it is not clear if its abnormalities could be related to an increased risk factor for arterial thrombotic complications. In vitro studies have shown that corticosteroids can reduce fibrinolytic activity by inducing the release of PAI-1 in liver and fibrosarcoma cells (24) . Previous studies reported controversial results about ATIII: sometimes it has increased or is unchanged in CS patients (10) . ATIII inhibits activated F8, F9, F10 and F12 and plays an important role in controlling coagulation, and its deficiency could be associated with thrombosis (29) .
Our findings confirm, in a large population, the high levels of VWF with subsequent reduction of aPTT levels and evidence of enhanced thrombin generation (high concentrations of TAT) together with an impaired fibrinolytic activity (increased PAI-1, ATIII and a 2 antiplasmin activities) in patients with untreated CS Table 4 Number of patients with CS before and after surgery with coagulation indexes above normal ranges.
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